Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Tampere Centre for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Eur J Pediatr. 2023 Jun;182(6):2665-2671. doi: 10.1007/s00431-023-04940-2. Epub 2023 Mar 29.
To evaluate the management of bronchiolitis in the paediatric intensive care unit (PICU) before and after publication of the national bronchiolitis guidelines in June 2015. All infants treated between 2016-2020 for bronchiolitis in the PICU of Tampere University Hospital at < 12 months of age were included. The data were retrospectively collected from electronic patient records. The current results reflecting the post-guideline era were compared with previously published results for the pre-guideline 2000-2015 period. These two studies used identical protocols. Forty-six infants treated in the PICU were included. During the post-guideline era, inhaled adrenaline was given to 26 (57%), salbutamol to 7 (15%), and hypertonic saline inhalations to 35 (75%) patients. Forty-three patients (94%) received high-flow oxygen therapy (HFOT). Seventeen patients (37%) were treated with nasal continuous positive airway pressure (CPAP) and 4 (9%) with mechanical ventilation.
When post-guideline years were compared with pre-guideline years, the use of bronchodilators decreased in agreement, but the use of inhaled saline increased in disagreement with the guidelines. The use of respiratory support increased, evidently because of an introduction of the non-invasive HFOT treatment modality.
• Oxygen supplementation and respiratory support, when needed, are the cornerstones of bronchiolitis treatment. • Medicines are frequently given to infants with bronchiolitis, especially if intensive care is needed, although evidence of their effectiveness is lacking.
• Nearly all (94%) infants who needed intensive care were treated with HFOT and 37% with nasal CPAP, and finally, only 9% were intubated, which reflects the effectiveness of non-invasive techniques. • When pre- and post-guideline eras were compared, use of racemic adrenaline decreased from 84 to 57%, but use of hypertonic saline increased up to 75%, which disagrees with the current guidelines.
评估 2015 年 6 月国家毛细支气管炎指南发布前后小儿重症监护病房(PICU)毛细支气管炎的管理情况。
纳入 2016-2020 年在坦佩雷大学医院 PICU 接受治疗且年龄<12 个月的毛细支气管炎患儿。从电子病历中回顾性收集数据。将反映指南后时代的当前结果与之前公布的 2000-2015 年指南前时期的结果进行比较。这两项研究使用了相同的方案。
46 例患儿入组。指南后时代,26 例(57%)患儿接受吸入肾上腺素,7 例(15%)接受沙丁胺醇,35 例(75%)接受高渗盐水吸入。43 例(94%)患儿接受高流量氧疗(HFOT)。17 例(37%)患儿接受鼻持续气道正压通气(CPAP)治疗,4 例(9%)患儿接受机械通气。
与指南前时代相比,指南后时代支气管扩张剂的使用减少,而与指南不一致的是,吸入盐水的使用增加。呼吸支持的使用增加,显然是由于引入了非侵入性 HFOT 治疗方式。
• 氧补充和呼吸支持是毛细支气管炎治疗的基石,需要时给予。• 尽管缺乏有效性证据,但毛细支气管炎患儿经常使用药物治疗,尤其是在需要重症监护的情况下。
• 几乎所有(94%)需要重症监护的患儿均接受 HFOT 治疗,37%接受鼻 CPAP 治疗,最终只有 9%患儿需要插管,这反映了非侵入性技术的有效性。• 与指南前时代相比,使用消旋肾上腺素从 84%降至 57%,但使用高渗盐水从 42%增至 75%,与当前指南不符。